Kakkar A1 and Mukherjee I2*
1Department of Minimally Invasive & Robotic Surgery, Grant Medical College, India
2Department of Minimally Invasive & Robotic Surgery, Florida Hospital Tampa, USA
Colorectal Cancer is the second leading cause of cancer death worldwide second only to lung cancer. Screening modalities have been developed by various medical organizations and that has shown a dip in the mortality rates. As the screening modalities vary from non-invasive fecal occult blood test to Colonoscopy, there is a large variation between the two spectra. Radiological imaging has tried to bridge this gap, but has failed to do so significantly. Recently the Food and Drug Administration of USA has approved for the use of a stool DNA test (Colorgurad®, Exact Science) and blood test (Epi proColon®) for Colorectal Cancer Screening. This article attempts to shows how the two new non investigations, being non-invasive, can be an integral part of the armament of a patient and his clinician for screening, diagnostic and monitoring for Colorectal Cancer.
Kakkar A, Mukherjee I. New Non- Invasive Genetic Studies in Colorectal Cancer. Clin Surg. 2017; 2: 1342.